Announcement

Collapse
No announcement yet.

The Lancet. β-agonists for ARDS: the dark side of adrenergic stimulation?

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • The Lancet. β-agonists for ARDS: the dark side of adrenergic stimulation?

    [Source: The Lancet, full text: (LINK). Extract, edited.]
    The Lancet, Early Online Publication, 12 December 2011

    doi:10.1016/S0140-6736(11)61845-X


    β-agonists for ARDS: the dark side of adrenergic stimulation?


    Original Text

    B Taylor Thompson


    In The Lancet , Fang Gao Smith and the BALTI-2 study investigators report the findings of their phase-3 randomised trial of intravenous salbutamol for acute respiratory distress syndrome (ARDS). The trial, based on reliable preclinical evidence and an encouraging phase-2 trial, was stopped early because of safety concerns. β-agonists had been an appealing therapeutic option for ARDS in view of extensive clinical experience, low cost, and an excellent safety profile when used for patients with obst (...)

    -
    ------
Working...
X